ATLG Levels During Stem Cell Transplant for Multiple Sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study measures how a specific immune-suppressing medication (ATLG) works in patients with multiple sclerosis who are undergoing autologous stem cell transplantation—a procedure where your own blood stem cells are removed, treated, and returned to help reset your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of multiple sclerosis (MS)
- Planned to receive autologous hematopoietic stem cell transplantation (HSCT) according to standard European guidelines
- Will receive ATLG (a specific immune-suppressing medication) as part of your pre-transplant conditioning regimen
- Not pregnant or breastfeeding
- No active uncontrolled infections at time of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if using your own stem cells can stop multiple sclerosis that keeps getting worse despite treatment. You would first receive a medication to reset your immune system, then get your stem cells back to help rebuild it.
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.